ArticleFrontiers in cardiovascular medicine2025
"Obesity, metabolic abnormalities and low-grade inflammation: differencial associations with subclinical atherosclerosis".
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impaired Myostatin Function Alters Body Composition Without Detectable Attenuation of Imiquimod-Induced Psoriasiform Dermatitis.International journal of molecular sciences · 2026Article
- Unmasking the role of hypertension in atherosclerosis among patients with obesity: a cardiometabolic dysfunction perspective.International journal of obesity (2005) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: Obesity is associated with an increased risk of atherosclerosis, though recent evidence shows conflicting results. This study aimed to evaluate whether obesity or its association with metabolic abnormalities (MAs) and low-grade inflammation play a more significant role in atherosclerosis development in a primary care population. Methods: A cross-sectional study using data from the Cardiometabolic Risk Factor Registry (CARFARE) at Hospital Universitario Austral included adults undergoing their first healthcare visit for primary cardiovascular prevention. Participants were classified into four groups: metabolically healthy non-obese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy non-obese (MUNO), and metabolically unhealthy obese (MUO), according to the BioShare-EU criteria and body mass index. MAs were defined by the same criteria. Inflammation was estimated through absolute Neutrophil (NEU) count. Atherosclerosis prevalence was analyzed using univariate analysis and multivariable logistic regression models. Results: Among 6,735 participants, 23.3% were MHNO, 3.13% MHO, 45.6% MUNO, and 27.9% MUO. MHO subjects were 10.1% of the obese population. In univariate analysis, atherosclerosis prevalence was higher in obese than non-obese individuals (57.1% vs. 52.0%, Conclusion: In this primary care population, the MHO phenotype was not associated with increased atherosclerosis. MAs and inflammation, rather than obesity alone, were independently associated with atherosclerosis. These findings highlight the need for further longitudinal studies to clarify the interactions between obesity and metabolic health in atherosclerosis development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.